Clarivate Plc filed its third-quarter 2026 earnings press release on November 3, 2026, reporting results for the three and nine months ended September 30, 2026, and updating its full-year financial outlook following the October 6, 2026 close of the Life Sciences and Healthcare segment divestiture.

Key Highlights

  • Total revenues (continuing operations): $481.6 million for Q3 2026, compared to $530.3 million in Q3 2025, according to the filing.
  • Net loss: $80.8 million, or $0.13 per diluted share, for Q3 2026, including a $62.2 million non-cash LS&H goodwill impairment charge, compared to a net loss of $28.3 million, or $0.04 per diluted share, in Q3 2025.
  • Adjusted EBITDA (including discontinued operations): $245.3 million for Q3 2026, compared to $252.4 million in Q3 2025.
  • LS&H divestiture closed: The company completed the sale of the LS&H segment on October 6, 2026, for net cash proceeds of $488.4 million.
  • Organic ACV growth: Organic ACV for continuing operations grew 1.8% compared to September 30, 2025.
  • Full-year 2026 revenue outlook: $1.965 billion to $1.985 billion, excluding discontinued operations.
  • Free cash flow (nine months): $233.1 million for the first nine months of 2026, compared to $276.1 million in the prior year period.

Clarivate Reports Q3 2026 Results and Revised Outlook After LS&H Sale

Clarivate Plc (NYSE:CLVT) reported third-quarter 2026 results showing total revenues from continuing operations of $481.6 million, down from $530.3 million in Q3 2025, with the decline attributed primarily to inorganic disposals, according to the filing. Organic revenues for continuing operations increased 0.4%, as organic subscription growth of 1.5% and organic re-occurring growth of 0.7% were partially offset by lower organic transactional revenues. Subscription revenues for continuing operations reached $338.3 million, up $2.4 million, or 0.7%, versus the prior-year quarter.

The company reported a net loss of $80.8 million, or $0.13 per diluted share, for Q3 2026, compared to a net loss of $28.3 million, or $0.04 per diluted share, in Q3 2025. The filing attributed the wider loss largely to a $62.2 million non-cash goodwill impairment charge related to the LS&H segment. On an adjusted basis, net income was $136.0 million, or $0.21 per diluted share, versus $119.3 million, or $0.18 per diluted share, a year earlier. For the nine months ended September 30, 2026, the net loss including LS&H was $389.6 million, or $0.61 per diluted share, driven in part by a $283.9 million non-cash LS&H goodwill impairment charge.

As of September 30, 2026, total debt outstanding was $4,176.1 million, a decrease of $293.8 million compared to the prior year, reflecting a $100.0 million accelerated debt repayment in January 2026 that fully redeemed senior secured notes due November 2026, as well as the retirement of $192.6 million aggregate principal of other senior notes at approximately a 5% discount to par. Following the reporting period, the company closed the LS&H sale on October 6, 2026, generating net cash proceeds of $488.4 million. The updated full-year 2026 outlook calls for adjusted diluted EPS of $0.73 to $0.77 and free cash flow of $320 million to $340 million, with all outlook figures excluding discontinued operations. The filing notes that these forward-looking statements assume no further acquisitions, divestitures, or unanticipated events and are subject to the company's cautionary language.

What Was Disclosed

Clarivate disclosed Q3 and nine-month 2026 financial results, including revenue, net loss, adjusted EBITDA, and cash flow figures, along with details of the completed LS&H segment divestiture and an updated full-year and Q4 2026 financial outlook excluding discontinued operations.